Institutional members access full text with Ovid®

Share this article on:

Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class With a Promising Future

Gartner, Elaina M. MD*; Burger, Angelika M. PhD; LoRusso, Patricia M. DO*

doi: 10.1097/PPO.0b013e3181d78223
Practice of Oncology: Recent Advances

Poly(ADP-ribose) polymerase inhibitors are an exciting new class of antineoplastic agents that impair the ability of cells to recover from DNA damage. They are most effective in the setting of inherent DNA repair defects, such as in cancers resulting from BRCA gene mutations, or in the setting of DNA-damaging chemotherapeutic agents. This article reviews the background and development of these agents in the laboratory, as well as the rationale for the biologic correlative studies used in clinical trials. The most recent data from the clinical trials of olaparib (AZD2281, KU-0059436), BSI-201, AG014699, ABT-888, and INO-1001 and descriptions of ongoing studies are also presented.

From the Departments of *Internal Medicine and †Pharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI.

Reprints: Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Hudson Webber Cancer Research Center, 4th Floor, 4100 John R Street, Detroit, MI 48201. E-mail: lorussop@karmanos.org.

© 2010 Lippincott Williams & Wilkins, Inc.